Navigation Links
Study Would Pave Way for the Development of New Drugs That Targets TB Proteasome

A new study was conducted to understand the biochemistry and structure of a protein-cleaving complex (proteasome) that is essential to the TB bacterium’s survival. The findings were published in the journal Molecular Microbiology. // The study’s main aim was to design effective treatment for the disease tuberculosis (TB). The study was done by scientists from the U.S. Department of Energy’s Brookhaven National Laboratory and collaborating institutions. Biophysicist Huilin Li, who led Brookhaven’s role in the research, said that the study also plans to analyze the difference present in the structure and biochemistry of the TB bacterial proteasome from those found in human cells. This would greatly improve prospects for developing specific proteasome-based anti-tuberculosis treatments.

Mycobacterium tuberculosis is the bacterium that causes TB in man. Statistics show that one out of three people is infected with the disease. Largely the infected person is not aware of the presence of the disease as it does not manifest any observable symptoms. This is due to the fact that the bacteria is kept in check within immune system cells known as macrophages by compounds such as nitric oxide that kills or disables most of the bacteria. Inside the macrophage the immune cells damages and destroys the bacterial proteins. These accumulated proteins have to be removed otherwise it will in turn destroy the cell.

But the TB bacteria remove the damaged proteins with the help of a protein-cleaving complex known as a proteasome. It is highly specific for degrading protein parts. This protein allows Mycobacterium tuberculosis to remain in macrophages, and possibly go on to cause active TB infections. Hence Li said this protein should be made as a major target for the production of new anti-TB drugs. By this technique TB microbes can be eradicated from infected individuals who show no signs of infection. But the major drawback is that human cells also contain proteaso mes for degrading unneeded proteins. This process is essential for human cell survival. So any drug targeting the TB proteasome would have to be extremely specific. Hence studies should be very specific in identifying the unique characteristics that would allow such a targeted drug design.

The studies reveal highly specific details of the proteasome active site and mechanism, which will be invaluable to designing TB specific inhibitors. The proteasome structure was revealed by Guiqing Hu and collaborators using cryo electron microscopy in Brookhaven Lab’s Biology Department and by x-ray crystallography at the Lab’s National Synchrotron Light Source. The biochemical studies were conducted at Weill Medical College of Cornell University by Gang Lin in a group led by Carl Nathan. Other collaborating institutions included the Max Planck Institute of Biochemistry, Cold Spring Harbor Laboratory, and Millennium Pharmaceuticals. This research was funded by the Office of Biological and Environmental Research within the U.S. Department of Energy’s Office of Science, the National Institutes of Health, and Brookhaven’s Laboratory Directed Research and Development program.

'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision ... executive staff with the addition of industry sales leader, Thomas (Tom) Slott, as ... the national distribution and sales network, direct the efforts of the surgical sales ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: